MedTrace Logo

Ivermectin for Post Exposure Prophylaxis of Covid-19

NCT05231603 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-10-18

No results posted yet for this study

Summary

Post exposure prophylaxis of healthy contacts is among the measures used for outbreak control of several infectious diseases (e.g., pandemic influenza). No agent is known to be effective in preventing COVID-19, but Ivermectin is one of the drugs that have shown antiviral activity against SARS-CoV-2 in the laboratory. This study aims to evaluate the effect of post exposure prophylaxis with Ivermectin after exposure to COVID-19 among the asymptomatic close contacts.

Conditions

Interventions

DRUG

Ivermectin

0.4 mg/kg/day-maximum dose is 24 mg.

OTHER

Placebo

Similar to drug in term of tablets

Sponsors & Collaborators

  • Hovid Berhad

    collaborator INDUSTRY

  • Clinical Research Centre, Malaysia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-16
Primary Completion
2022-05-31
Completion
2022-10-11

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05231603 on ClinicalTrials.gov